OMass Therapeutics

OMass Therapeutics Announces $310 Million Series C Financing to Advance Portfolio of Small Molecule Therapeutics in Endocrinology and Immunology

OMass Therapeutics Appoints Jonathan Montagu as Chair of the Board of Directors

OMass Therapeutics Enters into Exclusive Collaboration and License Agreement with Genentech to Develop and Commercialize Therapies for Inflammatory Bowel Disease

OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025

OMass Therapeutics to Present New Preclinical Data For its Best-in-Class MC2 Program at ENDO 2025